A Critical Evaluation of the Hypothesis that N,N-Dimethyltryptamine has Endogenous Functions
Ramiro Solis
Zenodo (CERN European Organization for Nuclear Research) June 22, 2026 preprint DOI: 10.5281/zenodo.20823985 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper |
|---|---|
| Topics | Serotonin 5-MeO-DMT DMT |
| Keywords | Endogeny Endogenous agonist 5-HT Receptor Intracellular Antidepressant Neurotransmitter receptor Function biology Enzyme |
| Key points | Argues that evidence for an endogenous physiological function of DMT is mixed and contested, with key findings not independently replicated and receptor affinity mismatches, and that clinical efficacy does not establish endogenous function. |
Abstract
The human body possesses enzymatic machinery to both synthesize and rapidly degrade N,N-dimethyltryptamine (DMT). This coexistence raises a question: does DMT serve an endogenous function, or is it a metabolic byproduct with no physiological role? DMT is structurally almost identical to serotonin and binds to the same serotonin receptors. Serotonin is universally accepted as a neurotransmitter with essential functions. If DMT were merely a metabolic byproduct, why would the body produce a molecule shaped like serotonin and binding to serotonin receptors through regulated enzymatic steps? This paper critically evaluates the hypothesis that DMT is an endogenous molecule with physiological functions. The evidence is mixed and contested. Barker (2025) reports DMT concentrations in the nM range, comparable to serotonin and dopamine. Palner et al. (2026) report that DMT is below the detection limit in rat brain. The sigma-1 receptor affinity (Ki ~14 μM) is three orders of magnitude higher than reported physiological concentrations. The intracellular 5-HT2A receptor finding (Barker 2025) has not been independently replicated. The dietary DMT gap has not been directly measured. Clinical trials demonstrate that high-dose DMT produces antidepressant effects (Erritzoe et al. 2026; Falchi-Carvalho et al. 2025), but clinical efficacy does not establish endogenous function. Based on this critical evaluation, a companion paper (Solis, 2026b) proposes and evaluates a focused hypothesis: that DMT maintains neuroplasticity, and that its decline may contribute to age-related cognitive decline. The present paper outlines a research program to test whether DMT has physiological functions, while acknowledging that the prior probability of endogenous function may be low given the current state of the evidence.
Comparable studies
Other theoretical and historical papers on 5-MeO-DMT, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| When the Endogenous Hallucinogenic Trace AmineN,N-Dimethyltryptamine Meets the Sigma-1 Receptor | 2009 | Theoretical or philosophical paper | |
| Analytical chemistry of synthetic routes to psychoactive tryptamines : Part I. Characterisation of the Speeter and Anthony synthetic route to 5-methoxy-N,N-diisopropyltryptamine using ESI-MS-MS and ESI-TOF-MS | 2004 | Theoretical or philosophical paper | |
| Enlightening the "Spirit Molecule": Photomodulation of the 5-HT2A Receptor by a Light-Controllable N,N-Dimethyltryptamine Derivative. | 2022 | Theoretical or philosophical paper | |
| Conformational, spectroscopic and nonlinear optical properties of biologically active N,N-dimethyltryptamine molecule: a theoretical study. | 2014 | Theoretical or computational study | |
| Simple syntheses of lespedamine and 5-bromo-n,n-dimethyltryptamine based on 1-hydroxyindole chemistry | 1995 | Theoretical or philosophical paper |